RESEARCH ARTICLE

Causes of death across categories of estimated glomerular filtration rate: The Stockholm CREAtinine Measurements (SCREAM) project

Björn Runesson1*, Abdul R. Qureshi1, Hong Xu2, Alessandro Gasparini3, Bengt Lindholm1, Peter Barany1, Carl G. Elinder1, Juan J. Carrero2

1 Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Technology and Intervention, Karolinska Institutet, Stockholm, Sweden, 2 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, 3 Department of Health Sciences, University of Leicester, Leicester, United Kingdom

* Bjorn.runesson@karolinska.se

Abstract

Introduction
Reduced kidney function increases the risk of death, but there is limited information on causes of death across stages of chronic kidney disease (CKD). We aimed to identify leading causes of death in community-dwelling individuals with differing kidney function.

Methods
Observational analysis from SCREAM, a healthcare utilization cohort of Stockholm, Sweden. We included all individuals who died during 2006–2012 and had one serum creatinine measured in the year prior to death. Using the CKD-EPI formula, we calculated eGFR and stratified individuals according to CKD stages. Causes of death were classified as cardiovascular (CVD), cancer, infection and other, using ICD-10 codes. We compared age- and sex-adjusted differences in the proportions of deaths from each cause.

Results
Out of 89,117 registered deaths, 70,547 (79%) had a recent eGFR estimation and were included in this study. Individuals had a median age of 82 (IQR 62–93) years and 52% were women. The proportions of deaths from CVD increased with lower eGFR, along with the proportion of deaths from infections. Deaths due to diabetes and genito-urinary diseases increased. Deaths due to cancer decreased, but other death causes did not vary. Within CVD causes of death, the proportion of arrhythmias and heart failure increased, but ischemic heart disease and cerebrovascular disease remained stable.

Conclusion
In a region-representative Swedish healthcare extraction, we observe differences regarding specific causes of death across different CKD stages. Increasing patient and provider...
and materials. There are no patents, products in development or marketed products associated with this research to declare.

Introduction

Chronic kidney disease (CKD) is a common but under-recognized health problem, affecting 5–10% of the European population, especially the elderly and the chronically ill [1, 2]. While it is well-known that low kidney function increases mortality [3–6], the pattern of causes of death associated with CKD stages has not been sufficiently described. Characterizing causes of death in the community in relation to kidney function is important, since the prevention and management of underlying diseases can be substantially different across increasing disease severity.

Available reports on this issue are scarce and derived from North American [4, 7], or Korean populations [6]. Because of differences in lifestyle, risk factors, clinical practice patterns, and healthcare access, comparisons with other countries and regions may be useful as a measure of the overall disease burden. Potentially, it may also serve to generate insights into mechanisms of disease and help to identify population segments where more intensive preventive strategies are needed. To this end, we used a large region-representative healthcare-extraction to examine the proportions of deaths attributable to various causes in people at varying levels of kidney function in Stockholm, Sweden.

Material and methods

Data source and study design

This study is based on the Stockholm CREAtinine Measurements (SCREAM) healthcare-utilization cohort [1], including all residents in the region of Stockholm, Sweden, that undertook at least one measurement of serum creatinine in ambulatory or hospital care during 2006–2011. Laboratory data were linked with regional and national administrative databases for complete information on healthcare utilization, dispensed drugs, validated renal replacement therapy endpoints and follow up for death. This repository captured 89% of deaths occurring during 2006–2011 in the Stockholm county, with non-captured deaths attributed to younger population segments (<65 years old) who less often accessed healthcare or had creatinine tested [1].

For this analysis, we identified adults aged ≥18 years old who were residing in Stockholm, died between January 1st, 2006 and March 31st, 2012, and had an outpatient serum creatinine measured in the year before death. Stockholm is the most populated region in Sweden, with a population of 1.8 million individuals in 2011. In Sweden, there is universal access to the publicly financed healthcare, which is provided by both public and private institutions. The institutional review board at Karolinska Institutet, Stockholm, Sweden and the Swedish National Board of Welfare approved the study.

Exposure and covariates

All creatinines were measured with either enzymatic or corrected Jaffe method (alkaline picrate reaction), both methods being traceable to isotope dilution mass spectroscopy standards. Inter- as well as intra-laboratory variation is considered minimal in the region, with the three laboratories being frequently audited for quality and harmonization by the national...
organization EQUALIS (www.equalis.se). For this study, we excluded creatinine laboratory tests measured at hospital and at the emergency department, as well as implausible values (<40 and >1500 mmol/L). We selected all remaining serum creatinine determinations >1 day before and within the year prior to death. If more than one eligible creatinine was available for a patient, we used the one closest to the time of death.

We used these serum creatinine measurements to determine the exposure, which is estimated glomerular filtration rate (eGFR) strata, using the 2009 CKD-EPI creatinine-based equation. Records of ethnicity are not available in Sweden, and in applying this equation, all individuals were considered Caucasians. Using the value closest in time, and up to one year before death, outpatient eGFR was categorized as >90, 90–60, 45–59.9, 30–44.9, 15–29.9 ml/min per 1.73 m², and end-stage renal disease (ESRD). The category ESRD included individuals with eGFR <15 ml/min per 1.73 m² as well as those undergoing maintenance dialysis (hemodialysis or peritoneal dialysis). Individuals with a renal transplant where assigned to the eGFR category of their eligible creatinine. Renal replacement therapy status was ascertained by linkage with the Swedish Renal Register (http://www.snronline.se). Because albuminuria was only available in 13% of the cohort [1], it could infer selection bias; we were therefore unable to study KDIGO CKD severity stages [8], and in this study we refer solely to eGFR strata.

All other covariates were calculated at the time of the index eGFR. Demographic variables included age at time of the index eGFR, and sex. We used validated algorithms to define the Charlson comorbidities at baseline using ICD-10 diagnoses issued in the preceding 5 years in connection to hospitalization and ambulatory care [9]. The Charlson Comorbidity Index score included the following 16 comorbidity domains: myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatic disease, mild liver disease, diabetes without chronic complication, diabetes with chronic complication, hemiplegia or paraplegia, renal disease, any malignancy, moderate or severe liver disease, metastatic solid tumor, aids/HIV. For Cardiovascular disease was defined as the composite of myocardial infarction, congestive heart failure, peripheral vascular disease and cerebrovascular disease.

**Study outcome**

The outcome was causes of death, as registered by the Swedish Population Register, which analyses death records and classifies underlying medical conditions according to the International Classification of Disease-10th revision (ICD-10). The population is updated monthly by the Swedish National Board of Welfare and is considered to have virtually no loss to follow up. For this study, we considered the primary assigned cause of death, which is coded to ICD-10 diagnoses from the written death certificates by the treating physician. Causes of death were divided into four main categories: cardiovascular, cancer, infection and other. Other causes included neurologic diseases, chronic lung diseases, digestive diseases, accidents (suicides included), diabetic complications, and miscellaneous (any cause not fitting the above). There were no missing causes of death. Cardiovascular causes of death were subdivided into ischemic heart disease, congestive heart failure, cerebrovascular disease, arrhythmia and valvular disease.

**Statistical analyses**

We report baseline descriptive statistics as counts and percentages or medians and interquartile ranges as appropriate. Chi-squared and Kruskal–Wallis tests were used to test for differences across groups. Using multinomial logistic regression models, we estimated likelihood of death from specific causes according to eGFR strata. We reported crude and age- and sex-
adjusted proportions of death by the different causes. We also present the subcategories associated with cardiovascular and other causes of death. In a sensitivity analyses, we excluded patients with eGFR values from the last 3 months before death in an attempt to eliminate influence of critical illness unrelated to chronic kidney dysfunction. Finally, we analyzed causes of death among men and women separately. Analyses were performed using Stata 14.2 (Stata Corp LLC, 4095 Lakeway drive, College Station, Tx 77846, USA) and SAS version 9.4 (SAS Campus Drive, Cary, NC, USA).

Results

Study flow-chart and participant characteristics

During the study period, a total of 1,120,868 adult healthcare users underwent creatinine testing in Stockholm. Of these, 89,117 individuals died. We excluded 17,620 of them because their closest ambulatory creatinine to calculate eGFR was taken more than 12 months prior to death. Further 950 individuals were excluded because the index creatinine was measured on the day of or the day prior to death (and presumably impacted by acute disease). At the end of the selection process, a total of 70,547 cases of death were included in the study (Fig 1).

Table 1 shows baseline characteristics of the study participants overall and according to the four main categories of death. The median age was 82 years (10th and 90th percentiles 62–93 years).
years) and 52% were women. A diagnosis of diabetes was found among 18% of participants, and 44% had a history of CVD. CVD was the most common cause of death (36% of deaths, n = 25,216), followed by cancer (31%, n = 21,941). Participants dying from cancer were younger and less often diabetic as compared to those dying from CVD or infection. Between 50 and 60% of cases, depending on the specific cause of death, had an eGFR $> 60$ ml/min.

### Main causes of death by eGFR strata

Fig 2 shows the (unadjusted) proportions of eGFR strata according to causes of death. Table 2 shows the unadjusted and age and sex adjusted proportions of death by cause and eGFR strata. Among those with an eGFR $> 90$ ml/min/1.73 m$^2$, cancer was the most common cause, responsible for 52% of deaths (95% CI, 51–53%). After age and sex adjustment, cancer remained the most common cause of death in this category (47% (95% CI 46–48%), followed by other causes (adjusted proportion 29% (95% CI 28–30%). Among participants with eGFR 60–89 ml/min/1.73 m$^2$, deaths attributed to cancer, CVD and other causes were similar in proportion and each approximated 30% of cases.

Among participants with eGFR $< 60$ ml/min/1.73 m$^2$, CVD appeared as the primary cause of death, with increasing proportion across lower eGFR strata (adjusted proportions of 41%, 45% and 46% of cases in the categories of eGFR 45–59, 30–44 and 15–29 ml/min/1.73 m$^2$, respectively). Among ESRD cases, CVD deaths (adjusted proportion 39% (95% CI 36.5–41.2%) and other causes of death (42% (95% CI 39.6–44.3%) were of similar magnitude. Deaths due to infections were also higher in participants with eGFR $< 60$ ml/min/1.73 m$^2$, with no detectable trends across lower eGFR strata.

**Other causes of death by eGFR strata.** Other causes of death are presented in Table 3 and Fig 3. Neurologic diseases (including dementia), chronic lung disease and accidents/suicide were the most common causes of death among individuals with eGFR $> 90$ ml/min/1.73 m$^2$, but their proportions decreased across lower eGFR strata (for instance, from an adjusted proportion for neurologic disease of 31% (95% CI 29.2–33.2%) in eGFR $> 90$ ml/min/1.73 m$^2$ to 9% (95% CI 7.1–11.4%) in ESRD participants). The proportion of deaths attributed to digestive diseases were similar across all eGFR strata. Conversely, minor causes of death, such as

### Table 1. Demographic and clinical characteristics of study participants, overall and by cause of death.

| Participant Characteristics | Overall | Death attributed to |
|-----------------------------|---------|---------------------|
|                            | N (%)   | CVD (95%)           |
|                            |         | Cancer (95%)        |
|                            |         | Infection (95%)     |
|                            |         | Other (95%)         |
| N (%)                      | 70,547 (100) | 25,216 (35.7)     |
| Age, years (median, 10th to 90th p) | 82 (62 to 93) | 86 (69 to 94)        |
| Women, N (%)               | 36,878 (52.3) | 13,573 (53.8)     |
| Diabetes, N (%)            | 12,855 (18) | 4,946 (19.6)       |
| CVD, N (%)                 | 31,393 (44.5) | 15,417 (61.1)     |
| Charlson score (median, 10th to 90th p) | 2 (0 to 8) | 2 (0 to 5)        |
| eGFR strata, ml/min/1.73 m$^2$ |         |                    |
| $> 90$, N (%)              | 12,538 (17.8) | 2,171 (8.6)         |
| 60–89, N (%)               | 28,937 (41.0) | 10,046 (39.8)      |
| 45–59, N (%)               | 12,260 (17.4) | 5,227 (20.7)       |
| 30–44, N (%)               | 9,868 (14) | 4,603 (18.3)       |
| 15–29, N (%)               | 5,229 (7.4) | 2,488 (9.9)        |
| ESRD                        | 1,715 (2.4) | 681 (2.7)          |

CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.

https://doi.org/10.1371/journal.pone.0209440.t001
diabetic complications, genitourinary diseases and miscellaneous causes, became increasingly more common among individuals with lower eGFR.

**Subcategories of cardiovascular causes of death by eGFR strata.** Fig 4 and Table 4 show a subclassification of cardiovascular causes of death by eGFR strata. Ischemic heart disease was the most common cardiovascular cause of death across all eGFR strata. Deaths attributed to cerebrovascular disease were the second most common cause of CVD-death among individuals with eGFR $>90$ ml/min/1.73 m$^2$, but their proportion progressively decreased with lower eGFR. Conversely, deaths attributed to heart failure, valvular disease and arrhythmias tended to be more common in participants with lower eGFR strata. The proportion of other (unclassified) CVD causes of death tended to slightly decrease with lower eGFR.

**Sensitivity and sex-specific analyses**

After excluding 36,610 patients with creatinine measures obtained during the last 90 days prior to death, proportions were similar to the main analysis (S3–S6 Tables).

We also explored possible sex-differences in causes of death (S7–S10 Tables). Briefly, at study inclusion, there were more women than men, and men had a higher prevalence of
diabetes (21% vs 15%, in women). In both sexes, CVD was the main cause of death with lower eGFR (S8 Table), although ischemic heart disease was more often reported as a cause of death in men than in women at all eGFR strata (46% vs 36% overall in men versus women, S9 Table). Death due to neurologic diseases, including dementia, more often affected women than men in all eGFR categories (35% vs 26% in eGFR >90, and 39% vs 25% in eGFR 60–89 ml/min/1.73 m$^2$). (S10 Table). Diabetes, on the other hand, was more often the cause of death in men compared to women (for instance, 10.5% vs 6.0% in eGFR 45–59 ml/min and 32.5% vs 21.2% in ESRD, S10 Table). Deaths due to accidents and suicides were more common in men than women (in total, 19% vs 11%)–a difference that persisted across all eGFR strata.

Discussion

In this region-representative population-based Swedish healthcare extraction, we observe that the pattern of causes of death differs across CKD stages. Our findings lend further validity to recent reports [3, 4, 6, 7] and expand these observations to Northern Europe. Besides confirming previous reports, we provide new information by including individuals with ESRD as a separate category and by providing a sex-specific analysis of causes of death.

An important observation in our study is the gradual increase in the age-sex-adjusted proportion of CVD deaths with lower eGFR strata, a shift that becomes apparent already in the category of eGFR<60–45 ml/min/1.73 m$^2$. This and preceding evidence [3, 4, 6, 7] illustrate collectively the burden that CVD imposes in individuals with CKD. A recent estimation from the 2013 Global Burden of Disease (GBD) consortium, suggested that reduced GFR was associated with 4% of deaths worldwide, and more than half of these attributable deaths were CVD related [10]. While numerous studies have demonstrated a consistent association between
reduced GFR and specific CV events [11–13], our analysis expands this evidence by exploring the differential distribution of these across eGFR strata.

Ischemic heart disease and cerebrovascular disease were the most common causes of CVD death overall, but we did not find striking differences in their proportion across worse eGFR strata. In contrast, deaths attributed to heart failure, arrhythmias and valvular disease tended to rise with lower eGFR. This observation is useful from a clinical perspective as different cardiovascular events require different interventions. From a mechanistic perspective, these observations support the hypothesis that other factors than atherosclerosis, such as vascular calcification and chronic volume overload, may be more intrinsically linked to increased cardiac workload at lower eGFR. Various mechanisms have been proposed, such as osteoblast-like cells formation, excess calciprotein particles and metabolic insults of calcium-phosphate retention, diabetes, dyslipidemia, or oxidative stress, in the vessel wall [14–16].

### Table 3. Unadjusted and age- and sex-adjusted proportions (with 95% CI) of deaths attributed to other causes by eGFR strata.

| eGFR, ml/min per 1.73 m² | Neurologic diseases (incl dementia) | Chronic Lung diseases | Accidents and suicides | Digestive diseases | Diabetic complications | Genito-urinary diseases | Miscellaneous |
|--------------------------|-------------------------------------|----------------------|-----------------------|-------------------|-----------------------|-------------------------|----------------|
| ≥90 ml/min/1.73 m²       | 20.2 (18.9 to 21.6)                 | 15.6 (14.4 to 16.8)  | 28.2 (26.7 to 29.7)   | 15.6 (14.4 to 16.8) | 4.4 (3.8 to 5.1)       | 0.40 (0.20 to 0.61)     | 15.5 (14.3 to 16.7) |
| Unadjusted               |                                      |                      |                       |                   |                       |                         |                |
| Age/sex adjusted         | 31.2 (29.2 to 33.2)                 | 21.2 (19.5 to 22.8)  | 15.5 (14.1 to 16.9)   | 12.1 (10.9 to 13.4) | 3.9 (3.2 to 4.6)       | 0.47 (0.22 to 0.72)     | 15.6 (14.2 to 17.0) |
| 60–89 ml/min/1.73 m²     | 35.9 (34.8 to 36.9)                 | 15.7 (15.0 to 16.5)  | 13.3 (12.6 to 14.0)   | 9.5 (8.9 to 10.2)   | 4.5 (4.1 to 5.0)       | 1.1 (0.89 to 1.4)       | 19.9 (19.1 to 20.1)  |
| Unadjusted               | 32.6 (31.5 to 33.7)                 | 15.2 (14.4 to 16.0)  | 14.7 (13.9 to 15.5)   | 10.2 (9.5 to 10.9)  | 4.8 (4.4 to 5.3)       | 1.1 (0.85 to 1.3)       | 21.4 (20.5 to 22.3)  |
| Age/sex adjusted         |                                      |                      |                       |                   |                       |                         |                |
| 45–59 ml/min/1.73 m²     | 30.8 (29.2 to 32.3)                 | 16.2 (14.9 to 17.4)  | 11.9 (10.8 to 12.9)   | 10.3 (9.3 to 11.3)  | 7.3 (6.4 to 8.2)       | 2.3 (1.8 to 2.8)        | 21.4 (20.0 to 22.8)  |
| Unadjusted               | 26.8 (25.3 to 28.4)                 | 15.2 (14.0 to 16.5)  | 13.7 (12.4 to 15.0)   | 11.3 (10.2 to 12.5) | 7.9 (6.9 to 8.9)       | 2.2 (1.7 to 2.7)        | 22.8 (21.3 to 24.3)  |
| Age/sex adjusted         |                                      |                      |                       |                   |                       |                         |                |
| 30–44 ml/min/1.73 m²     | 26.7 (25.0 to 28.4)                 | 14.8 (13.5 to 16.2)  | 12.3 (11.0 to 13.5)   | 10.8 (9.6 to 12.0)  | 10.0 (8.9 to 11.2)     | 4.2 (3.5 to 5.0)        | 21.1 (19.6 to 22.7)  |
| Unadjusted               | 22.8 (21.2 to 24.4)                 | 13.8 (12.5 to 15.1)  | 14.3 (12.9 to 15.7)   | 11.9 (10.6 to 13.2) | 10.9 (9.6 to 12.1)     | 4.0 (3.3 to 4.8)        | 22.2 (20.1 to 23.9)  |
| Age/sex adjusted         |                                      |                      |                       |                   |                       |                         |                |
| 15–29 ml/min/1.73 m²     | 20.0 (18.0 to 22.0)                 | 10.5 (9.0 to 12.1)   | 10.7 (9.1 to 12.3)    | 12.3 (10.6 to 13.9) | 12.6 (10.9 to 14.3)    | 12.3 (10.7 to 12.0)     | 21.6 (19.5 to 23.7)  |
| Unadjusted               | 17.4 (15.5 to 19.2)                 | 9.8 (8.3 to 11.3)    | 12.0 (10.3 to 13.8)   | 13.1 (11.3 to 14.9) | 13.4 (11.6 to 15.1)    | 11.7 (10.0 to 13.4)     | 22.6 (20.4 to 22.8)  |
| Age/sex adjusted         |                                      |                      |                       |                   |                       |                         |                |
| ESRD                     | 9.5 (7.3 to 11.7)                   | 4.0 (2.5 to 5.4)     | 3.3 (2.0 to 4.6)      | 4.8 (3.2 to 6.4)    | 26.1 (23.0 to 29.4)    | 36.9 (33.4 to 40.5)     | 15.3 (12.7 to 18.0)   |
| Unadjusted               | 9.3 (7.1 to 11.4)                   | 4.0 (2.5 to 5.4)     | 3.1 (1.9 to 4.4)      | 4.9 (3.3 to 6.5)    | 26.8 (23.4 to 30.1)    | 35.5 (31.9 to 39.2)     | 16.4 (13.6 to 19.2)   |
| Age/sex adjusted         |                                      |                      |                       |                   |                       |                         |                |
| Total (cases)            | 5843                                | 2994                 | 3012                  | 2198              | 1421                  | 740                     | 3932            |

https://doi.org/10.1371/journal.pone.0209440.t003
Cancer was the main cause of death in individuals with eGFR >90 ml/min/1.73 m² in our study, but progressively moved to second and third place with lower eGFR. Again, these proportion estimates again agree with those of other countries [3, 4, 6, 7] and may be explained by other complications (namely cardiovascular diseases and infections) superseding the likelihood of dying from cancer, which occurs more commonly at older ages. We note that in prospective analyses, the association between eGFR and cancer death is, at most, weak and inconclusive [6, 17, 18], possibly because of insufficient control of confounders in registry-based analyses. One UK study that accounted for important confounders such as blood pressure and lipids could not observe any significant association of CKD, defined as reduced eGFR or elevated proteinuria, with cancer mortality [19]. Additionally, it is also possible that cancer incidence (notably renal and urothelial cancers) [20] increases with lower eGFR, but that such patients die of other causes.

Fig 3. Unadjusted proportions of other causes of death by eGFR strata. The height of each colored bar represents the percentage of participants for each cause of death within each category of eGFR. The width of the bar represents the percentage of participants for each eGFR category within each cause of death. The area of each colored bar represents the percentage of participants within each eGFR category and each cause of death.

https://doi.org/10.1371/journal.pone.0209440.g003
Deaths due to infection increased in patients with eGFR < 60 ml/min/1.73 m², and remained similarly elevated with lower eGFR categories. This agrees with population-based studies suggesting that the incidence of community-acquired infections overall and of those severe enough to require hospitalization are generally increased with lower eGFR, and are accounted for primarily by pneumonia, urinary tract infections, sepsis/bacteremia and cystitis [21–24]. It has been proposed that there is a biologic plausibility for the causality in these associations given the well-known effect of uremic toxicity on T lymphocyte and antigen-presenting cells [25] and the generation of oxidative stress [26], factors that alter both cellular and humoral immunity. Further, this may also be generally explained by excess comorbidity and frailty associated with CKD, which increase both the susceptibility to illness and the risk of subsequent death.

A novelty in our study is the performance of sex-specific analyses, in view of the insufficiently understood gender differences in CKD epidemics and outcomes [27, 28]. Although sex-
specific causes of death agree in general with our main analysis, there are some intriguing differences. For instance, death due to ischemic heart disease seems more common among men throughout all CKD strata. This agrees with the general population knowledge that death from coronary heart disease is more common in men than in women, although the gap between sexes is thought to narrow after menopause [29]. Also in agreement with previous knowledge, cancer, accidents and diabetes were more common among men [30]. Conversely, deaths attributed to neurologic diseases and dementias were higher in women, an issue possibly explained by the well-described longer life expectancy of women in the general population.

In the interpretation of our findings, we remind the reader that in this study we investigate pattern of causes of deaths, not mortality rates. It is indeed well-described that all-causes of death, both cardiovascular and non-cardiovascular, increase with lower eGFR [3–6]. For instance, in the region of Stockholm where our study takes place, Neovius et al. reported a hazard ratio of 4.1 and 3.3 for CVD and non-CVD mortality, respectively, in patients with CKD stages IV-V compared to persons with normal kidney function [31]. Our analysis, however, addresses a complementary question: although mortality risk may be increased, the event can be less frequent/common in proportion, which can be useful to inform patients and physicians of likely risks. For instance, although cancer-related mortality is increased with lower eGFR [32], we observe that their relative proportion is, however, less common, as other causes of death override.

The reader should also bear in mind some study strengths, such as the large and region-representative coverage of the sampling, with universal healthcare (which minimizes healthcare access bias) and government centralized outcome ascertainment with virtually no losses to follow up. Nevertheless, we have other limitations, mainly related to the inherent biases of using ICD reporting in administrative databases for causes of death [33], especially in comorbid and

| eGFR strata                  | Ischaemic heart Disease | Cerebrovascular disease | Heart Failure | Arrhythmia | Valvular disease | Other CVD causes |
|------------------------------|-------------------------|-------------------------|--------------|------------|-----------------|-----------------|
| ≥90 ml/min/1.73 m²           |                         |                         |              |            |                 |                 |
| Unadjusted                   | 47.5 (45.4 to 49.6)     | 23.0 (21.2 to 24.7)     | 6.3 (5.3 to 7.3) | 2.1 (1.5 to 2.7) | 1.4 (0.9 to 1.9) | 19.7 (18.0 to 21.4) |
| Age/sex adjusted             | 41.6 (34.2 to 50.0)     | 27.3 (22.2 to 32.4)     | 8.9 (6.8 to 11.0) | 2.8 (-13.7 to 19.4) | 1.3 (0.8 to 1.9) | 18.0 (14.5 to 21.6) |
| 60–89 ml/min/1.73 m²         |                         |                         |              |            |                 |                 |
| Unadjusted                   | 37.6 (36.6 to 38.5)     | 23.3 (22.5 to 24.1)     | 11.8 (11.2 to 12.4) | 7.5 (7.0 to 8.0) | 2.5 (2.2 to 2.8) | 17.3 (16.6 to 18.1) |
| Age/sex adjusted             | 38.1 (22.2 to 54.0)     | 23.4 (13.6 to 33.2)     | 11.3 (6.5 to 16.0) | 7.0 (-32.0 to 46.0) | 2.5 (1.4 to 3.6) | 17.8 (10.3 to 25.1) |
| 45–59 ml/min/1.73 m²         |                         |                         |              |            |                 |                 |
| Unadjusted                   | 39.2 (37.9 to 40.5)     | 19.5 (18.4 to 20.6)     | 13.2 (12.3 to 14.1) | 9.4 (8.6 to 10.2) | 3.4 (2.9 to 3.9) | 15.3 (14.3 to 16.3) |
| Age/sex adjusted             | 40.7 (19.9 to 61.5)     | 19.3 (9.4 to 29.2)      | 12.2 (5.9 to 19.0) | 8.5 (-38.4 to 55.5) | 3.5 (1.7 to 5.4) | 15.8 (7.7 to 23.8) |
| 30–44 ml/min/1.73 m²         |                         |                         |              |            |                 |                 |
| Unadjusted                   | 39.8 (38.4 to 41.3)     | 16.7 (15.6 to 16.7)     | 15.1 (14.1 to 16.1) | 8.5 (7.7 to 9.3) | 4.4 (3.8 to 5.0) | 15.5 (14.4 to 16.5) |
| Age/sex adjusted             | 41.3 (22.2 to 60.4)     | 16.5 (8.8 to 24.1)      | 14.0 (7.5 to 20.5) | 7.7 (-35 to 50.5) | 4.6 (2.4 to 6.7) | 16.0 (8.5 to 23.4) |
| 15–29 ml/min/1.73 m²         |                         |                         |              |            |                 |                 |
| Unadjusted                   | 44.2 (42.3 to 46.2)     | 11.9 (10.6 to 13.2)     | 18.3 (16.8 to 19.8) | 7.2 (6.2 to 8.2) | 4.0 (3.2 to 4.8) | 14.4 (13.0 to 15.8) |
| Age/sex adjusted             | 45.7 (27.6 to 63.8)     | 11.8 (7.0 to 16.6)      | 17.1 (10.2 to 23.9) | 6.6 (-30.5 to 43.7) | 4.1 (2.3 to 5.9) | 14.8 (8.8 to 20.1) |
| ESRD                         |                         |                         |              |            |                 |                 |
| Unadjusted                   | 53.8 (50.1 to 57.5)     | 11.5 (9.2 to 13.9)      | 15.5 (12.8 to 18.2) | 3.2 (1.9 to 4.5) | 3.1 (1.8 to 4.4) | 12.9 (10.4 to 15.4) |
| Age/sex adjusted             | 53.0 (42.3 to 63.6)     | 12.0 (8.6 to 15.4)      | 15.7 (11.6 to 19.8) | 3.1 (-15.3 to 21.6) | 3.1 (1.7 to 4.6) | 13.1 (9.5 to 16.6) |
| Total (cases)                | 10201                   | 5026                    | 3285         | 1888       | 683             | 4,133           |

CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.

https://doi.org/10.1371/journal.pone.0209440.t004
complex patients such as the elderly and those with advanced CKD. Even so, because of strong similarities with reports from other countries, we are confident of the potential generalizability of our findings. We used single measurement of eGFR, which may lead to misclassification of exposure. For that reason, in part, our analysis attempted to select the closest ambulatory eGFR estimation prior to death, which may more representative of their true kidney function when the event occurred. Further, we did a sensitivity analysis that excluded all eGFR measurements within three months before death and results were like those in the primary analysis. Unfortunately, we could not assess the associations with albuminuria because this metric is less often investigated in healthcare in our region and therefore would impose a strong selection bias.

To conclude, in this region-representative Swedish healthcare extraction, we report differences regarding causes of death across different CKD stages. Because prevention and management can be substantially different across diseases, our study may have implications for both clinical management and public health. Although CKD has been associated with an increased risk of many adverse health outcomes, characterizing the relative distribution of cause-specific deaths by eGFR category provides a comprehensive description of the cause-specific burden of disease in CKD. This information may be helpful for prioritizing resource allocation to future interventions, and inform decisions regarding patient management, emphasis on prevention strategies, and health service planning. For instance, deaths attributed to genitourinary diseases rise, perhaps not unexpectedly, with lower eGFR in our study, something that could be explained by reverse causation. However, it is still an important observation, given that most individuals with CKD in the greater community are unaware of their kidney dysfunction, and may not even be diagnosed [1], and this information can be used to justify more thorough patient investigations if in suspicion of disease.

Supporting information

S1 Table. Classification of causes of death according to ICD-10 codes. ICD, International Classification of Diseases, 10th revision.

S2 Table. eGFR strata, by sex.

S3 Table. Sensitivity analysis. Participant characteristics after exclusion of creatinine measurements from the last 90 days of life. CVD, cardiovascular disease, eGFR, estimated glomerular filtration rate, ESRD, end-stage renal disease.

S4 Table. Sensitivity analysis. Causes of death after exclusion of creatinine measures from the last 90 days of life. CVD, cardiovascular disease, eGFR, estimated glomerular filtration rate, ESRD, end-stage renal disease

S5 Table. Sensitivity analysis. Other causes of death after exclusion of creatinine measures from the last 90 days of life.

S6 Table. Sensitivity analysis. CVD causes of death after exclusion of creatinine measures from the last 90 days of life.
S7 Table. Female and male participant characteristics. CVD, cardiovascular disease.

S8 Table. Age-adjusted proportions (in %) in causes of death for men and women separately. CVD, cardiovascular disease, ESRD, end stage renal disease.

S9 Table. Age adjusted proportions (in %) of cardiovascular causes of death for men and women separately. CVD, cardiovascular disease.

S10 Table. Age adjusted proportions (in %) of other causes of death for men and women separately. Misc., miscellaneous. ESRD, end stage renal disease.

Acknowledgments
This study was supported by the Swedish Heart and Lung Foundation, the Stockholm County Council, Martin Rind's and Westman's Foundations. Baxter Novum is supported by a grant from Baxter Healthcare to Karolinska Institutet.

Author Contributions
Conceptualization: Björn Runesson, Juan J. Carrero.
Data curation: Björn Runesson, Abdul R. Qureshi.
Formal analysis: Björn Runesson, Juan J. Carrero.
Funding acquisition: Juan J. Carrero.
Investigation: Björn Runesson.
Methodology: Björn Runesson, Abdul R. Qureshi.
Software: Abdul R. Qureshi.
Supervision: Juan J. Carrero.
Writing – original draft: Björn Runesson.
Writing – review & editing: Hong Xu, Alessandro Gasparini, Bengt Lindholm, Peter Barany, Carl G. Elinder, Juan J. Carrero.

References
1. Gasparini A, Evans M, Coresh J, Grams ME, Norin O, Qureshi AR, et al. Prevalence and recognition of chronic kidney disease in Stockholm healthcare. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2016; 31 (12):2086–94. https://doi.org/10.1093/ndt/gfw354 PMID: 27738231; PubMed Central PMCID: PMCPMC5146708.
2. Bruck K, Stel VS, Gambaro G, Hallan S, Volzke H, Arnlov J, et al. CKD Prevalence Varies across the European General Population. Journal of the American Society of Nephrology: JASN. 2016; 27 (7):2135–47. Epub 2015/12/25. https://doi.org/10.1681/ASN.2015050542 PMID: 26701975; PubMed Central PMCID: PMCPMC4926978.
3. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet (London, England). 2013; 382(9889):339–52. Epub 2013/06/04. https://doi.org/10.1016/s0140-6736(13)60595-4 PMID: 23727170.
4. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr. Cause-Specific Deaths in Non-Dialysis-Dependent CKD. Journal of the American Society of Nephrology: JASN. 2015; 26(10):2512–20. Epub 2015/06/06. https://doi.org/10.1681/ASN.2014101034 PubMed Central PMCID: PMCPMC4587705. PMID: 26045089

5. Carrero JJ, Grams ME, Sarnak J, Amorim J, Gasparini A, Matsushita K, et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney international. 2017; 91(1):244–51. Epub 2016/12/09. https://doi.org/10.1016/j.kint.2016.09.037 PMID: 27927597.

6. Mok Y, Matsushita K, Sang Y, Ballew SH, Grams M, Shin SY, et al. Association of Kidney Disease Measures with Cause-Specific Mortality: The Korean Heart Study. PLoS One. 2016; 11(4):e0153429. Epub 2016/04/20. https://doi.org/10.1371/journal.pone.0153429 PMID: 27092843; PubMed Central PMCID: PMCPMC4836674.

7. Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klassenbach S, et al. Cause of Death in Patients with Reduced Kidney Function. Journal of the American Society of Nephrology: JASN. 2015; 26(10):2504–11. Epub 2015/03/04. https://doi.org/10.1681/ASN.2014070714 PMID: 25733523; PubMed Central PMCID: PMCPMC4587895.

8. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease outcomes initiative CKD-EPI equation. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2011; 58(5):675–90. Epub 2011/04/23. PMID: 21565071.

9. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. Journal of clinical epidemiology. 2003; 56(3):221–9. Epub 2003/05/03. PMID: 12725876.

10. Thomas B, Matsushita K, Abate KH, Al-Aly Z, Amrlov J, Asayama K, et al. Global Cardiovascular and Renal Outcomes of Reduced GFR. Journal of the American Society of Nephrology: JASN. 2017; 28(7):2167–79. Epub 2017/04/15. https://doi.org/10.1681/ASN.2016050562 PMID: 28408440; PubMed Central PMCID: PMCPMC5491277.

11. Matsushita K, Ballew SH, Coresh J, Arima H, Amrlov J, Cirillo M, et al. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. The lancet Diabetes & endocrinology. 2017; 5(9):718–28. Epub 2017/07/19. https://doi.org/10.1016/s2213-8587(17)30183-3 PMID: 28716631; PubMed Central PMCID: PMCPMC649254.

12. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottlieiner JS, Krommal RA, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. Journal of the American College of Cardiology. 2003; 41(8):1364–72. Epub 2003/04/23. PMID: 12706933.

13. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. Journal of the American College of Cardiology. 2003; 41(1):47–55. Epub 2003/02/07. PMID: 12570944.

14. London GM, Marchais SJ, Guerin AP, Metivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Current opinion in nephrology and hypertension. 2005; 14(6):525–31. Epub 2005/10/06. PMID: 16205470.

15. Palloin NJ, Giachelli CM. A current understanding of vascular calcification in CKD. American journal of physiology Renal physiology. 2014; 307(8):F891–900. Epub 2014/08/22. https://doi.org/10.1152/ajprenal.00163.2014 PMID: 25143458; PubMed Central PMCID: PMCPMC4200295.

16. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. Journal of the American Society of Nephrology: JASN. 2009; 20(7):1453–64. Epub 2009/05/30. https://doi.org/10.1681/ASN.2008070692 PMID: 19478096.

17. Weng PH, Hung KY, Huang HL, Chen JH, Sung PK, Huang KC. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clinical journal of the American Society of Nephrology: CJASN. 2011; 6(5):1121–8. Epub 2011/04/23. https://doi.org/10.2215/CJN.09011010 PMID: 21511834; PubMed Central PMCID: PMCPMC3087779.

18. Iff S, Craig JC, Turner R, Chapman JR, Wang JJ, Mitchell P, et al. Reduced estimated GFR and cancer mortality. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2014; 63(1):23–30. Epub 2013/09/03. https://doi.org/10.1053/ajkd.2013.07.008 PMID: 23993153.

19. Di Angelantonio E, Chowdhury R, Sarwar N, Aspeland T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ (Clinical research ed). 2010; 341:c4986. Epub 2010/10/05. https://doi.org/10.1136/bmj.c4986 PMID: 20884698; PubMed Central PMCID: PMCPMC2948649.

20. Lowrance WT, Ondroz J, Udaltsova N, Russo P, Go AS. CKD and the risk of incident cancer. Journal of the American Society of Nephrology: JASN. 2014; 25(10):2327–34. Epub 2014/05/31. https://doi.org/10.1681/ASN.2013060604 PMID: 24876115; PubMed Central PMCID: PMCPMC4178430.
21. McDonald HI, Thomas SL, Millett ER, Nitsch D. CKD and the risk of acute, community-acquired infections among older people with diabetes mellitus: a retrospective cohort study using electronic health records. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2015; 66(1):60–8. Epub 2015/02/03. https://doi.org/10.1053/j.ajkd.2014.11.027 PMID: 25641062; PubMed Central PMCID: PMCPMC4510204.

22. Xu H, Gasparini A, Ishigami J, Mzayen K, Su G, Barany P, et al. eGFR and the Risk of Community-Acquired Infections. Clinical journal of the American Society of Nephrology: CJASN. 2017; 12(9):1399–408. Epub 2017/08/19. https://doi.org/10.2215/CJN.00250117 PMID: 28818849; PubMed Central PMCID: PMCPMC4510204.

23. Ishigami J, Grams ME, Chang AR, Carrero JJ, Coresh J, Matsushita K. CKD and Risk for Hospitalization With Infection: The Atherosclerosis Risk in Communities (ARIC) Study. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2016. Epub 2016/11/26. https://doi.org/10.1053/j.ajkd.2016.09.018 PMID: 27894474; PubMed Central PMCID: PMCPMC5438909.

24. James MT, Quan H, Tonelli M, Manns BJ, Faris P, Laupland KB, et al. CKD and risk of hospitalization and death with pneumonia. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2009; 54(1):24–32. Epub 2009/05/19. https://doi.org/10.1053/j.ajkd.2009.04.005 PMID: 19447535.

25. Eleftheriadis T, Antoniadis G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Seminars in dialysis. 2007; 20(5):440–51. Epub 2007/09/28. https://doi.org/10.1111/j.1525-139X.2007.00283.x PMID: 17897251.

26. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Seminars in dialysis. 2009; 22(6):636–43. Epub 2009/12/19. https://doi.org/10.1111/j.1525-139X.2009.00659.x PMID: 20017834.

27. Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nature reviews Nephrology. 2018; 14(3):151–64. Epub 2018/01/23. https://doi.org/10.1038/nrneph.2017.181 PMID: 29355169.

28. Cobo G, Hecking M, Port FK, Exner I, Lindholm B, Stenvinkel P, et al. Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. Clinical science (London, England: 1979). 2016; 130(14):1147–63. Epub 2016/06/03. https://doi.org/10.1042/cs20160047 PMID: 27252402.

29. Shah T, Palaskas N, Ahmed A. An Update on Gender Disparities in Coronary Heart Disease Care. Current atherosclerosis reports. 2016; 18(5):28. Epub 2016/04/01. https://doi.org/10.1007/s11883-016-0574-5 PMID: 27029220.

30. Ostan R, Monti D, Guerisi P, Bussolotto M, Franceschi C, Baggio G. Gender, aging and longevity in humans: an update of an intriguing/neglected scenario paving the way to a gender-specific medicine. Clinical science (London, England: 1979). 2016; 130(19):1711–25. Epub 2016/08/25. https://doi.org/10.1042/cs20160004 PMID: 27555614; PubMed Central PMCID: PMCPMC4994139.

31. Neovius M, Jacobson SH, Eriksson JK, Elinder CG, Hylander B. Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study. BMJ open. 2014; 4(2):e004251. Epub 2014/02/20. https://doi.org/10.1136/bmjopen-2013-004251 PMID: 24549162; PubMed Central PMCID: PMCPMC3931988.

32. de Jager DJ, Vervloet MG, Dekker FW. Noncardiovascular mortality in CKD: an epidemiological perspective. Nature reviews Nephrology. 2014; 10(4):208–14. Epub 2014/02/05. https://doi.org/10.1038/nrneph.2014.8 PMID: 24492321.

33. Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-death statement. Archives of internal medicine. 2001; 161(2):277–84. Epub 2001/02/15. PMID: 11176744.